The Huang Lab was established in 2009 at the University of Chicago and has since been active in conducting pharmacogenomic research. In 2017, our laboratory moved to the University of Minnesota, where we continue that research.
Our main research focus is translational pharmacogenomics with a particular interest in the pharmacogenomics of anticancer agents. By systematically evaluating the human genome and its relationships to drug response and toxicity, our goal is to develop clinically useful models that predict risk for adverse drug reactions and nonresponse prior to administration of chemotherapy. Specifically, the theme of our research evolved around the idea of cell-based pharmacogenomics, which utilizes in vitro models for biomarker discovery and prediction-model construction, followed by in vivo validation. We routinely use cell lines (derived from healthy and diseased individuals as well as commercially available cancer cell lines) and clinical samples to discover and functionally characterize genetic variation and gene, miRNA, and long noncoding RNA expression for their roles in drug sensitivity.
We are proud to announce Amy's successful defense of her preliminary exam! Congratulations on officially becoming a PhD candidate!
Congratulations to our lab PI, Dr. R. Stephanie Huang, for being promoted to professor with tenure in the Department of Experimental & Clinical Pharmacology!
Congratulations to Weijie on being rewarded the 2022-2023 Interdisciplinary Doctoral Fellowship! Offical announcement and more information can be found on https://grad.umn.edu/news-events/news-overview/2022-2023-interdisciplinary-doctoral-fellowship-recipients-announced
To see past announcements, visit our archives here!